Augmentation of Creatine in the Heart

Heart failure and ischaemia disrupt energy supply in cardiomyocytes. Creatine buffering helps meet energy demands. However, creatine levels fall in heart disease. This gap motivated investigation into creatine elevation. Prior research has shown creatine's role in energy transport. No prior work had resolved how to raise myocardial creatine effectively. Dietary supplementation fails due to transporter down-regulation. Genetic studies suggest transporter activation may help.

This review aimed to evaluate evidence for creatine elevation in heart disease. The authors sought to identify barriers to raising myocardial creatine. They focused on the creatine transporter's role in limiting uptake. The study examined current pharmacological approaches. The goal was to determine if transporter activation is viable. No prior work had tested creatine esters in the heart. The authors wanted to assess the clinical potential of transporter activation. Their analysis targeted both preclinical and translational challenges.

The authors reviewed literature on creatine's role in heart energy metabolism. They examined dietary supplementation studies in animal models. They analyzed data on creatine transporter regulation in heart failure. They evaluated attempts to bypass the transporter via esters. They considered genetic overexpression studies in mice. They assessed small molecule activators of the transporter. The review focused on mechanisms of creatine uptake and regulation. They compared outcomes of different augmentation strategies.

Dietary creatine fails to raise myocardial levels due to transporter down-regulation. Creatine esters have not been tested in heart studies. Genetic overexpression of the transporter protects against ischaemia. This suggests transporter activation could be beneficial. No small molecule activators are currently available. The transporter's regulation remains poorly understood. This limits clinical translation of findings. The evidence supports further research into transporter modulation.

The authors propose that creatine elevation may protect the heart from ischaemia. They suggest that transporter activation is a promising target. However, no clinical studies confirm this yet. The evidence is limited to preclinical models. The authors suggest that transporter regulation is key to success. They propose that small molecule activators are needed. No prior work has tested these in the heart. The authors conclude that transporter activation requires further investigation.